- Conditions
- Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
- Interventions
- Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral, Placebo IV
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 1,751
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
- Interventions
- Durvalumab, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, External beam radiation (dose level 1), External beam radiation (dose level 2), External beam radiation (hyperfractionated), Cisplatin (dose level 1), Cisplatin (dose level 2), External beam radiation (standard)
- Drug · Radiation
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Aurora, Colorado • Houston, Texas
- Conditions
- Bladder Cancer, Muscle-invasive Bladder Cancer
- Interventions
- Methotrexate, Doxorubicin, vinblastine, cisplatin, Pegfilgrastim
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Burlington, Massachusetts • Pittsburgh, Pennsylvania
- Conditions
- Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 177
- States / cities
- Anchorage, Alaska • Burbank, California • Dublin, California + 109 more
- Conditions
- Ovarian Cancer Recurrent
- Interventions
- Rintatolimod, Pembrolizumab, Cisplatin
- Drug
- Lead sponsor
- Robert Edwards
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- tipifarnib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bryostatin 1, cisplatin
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- cisplatin, paclitaxel, adjuvant therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 59 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Paclitaxel, Carboplatin, Cetuximab, Docetaxel, Cisplatin, Fluorouracil, Radiotherapy (RT), Chemotherapy
- Drug · Radiation · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 29
- States / cities
- San Diego, California • Plainville, Connecticut • Weston, Florida + 19 more
- Conditions
- Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
- Interventions
- Cisplatin, Doxorubicin, Methotrexate, Pegfilgrastim, Pembrolizumab, Radical Cystectomy, Vinblastine Sulfate
- Drug · Biological · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cholangiocarcinoma
- Interventions
- CX-4945, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- Senhwa Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 3 more
- Conditions
- Head and Neck Cancer
- Interventions
- MEHD7945A, cetuximab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 14
- States / cities
- Stanford, California • Aurora, Colorado • Miami, Florida + 10 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
- Interventions
- LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 87
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more
- Conditions
- Esophageal Cancer
- Interventions
- cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Lung Cancer
- Interventions
- Nivolumab, Ipilimumab, Placebo
- Biological · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 907 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 28
- States / cities
- Sacramento, California • New Haven, Connecticut • Fort Myers, Florida + 23 more
- Conditions
- Malignant Mesothelioma
- Interventions
- cisplatin, pemetrexed disodium
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • New York, New York • Cleveland, Ohio
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- AGS-003-LNG, Carboplatin, Abraxane, Alimta, Cisplatin, Taxol, Radiation Therapy
- Biological · Drug · Radiation
- Lead sponsor
- GU Research Network, LLC
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Resectable Intrahepatic Cholangiocarcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine, Magnetic Resonance Imaging, Resection
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 57
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 47 more
- Conditions
- Advanced Solid Tumors
- Interventions
- YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)
- Drug
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Denver, Colorado • North Haven, Connecticut + 7 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Sacituzumab Govitecan-hziy (SG), Docetaxel
- Biological · Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 603 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 37
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 33 more
- Conditions
- Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- Carboplatin, Cisplatin, Doxorubicin Hydrochloride, Filgrastim, Laboratory Biomarker Analysis, Paclitaxel, Pegfilgrastim, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2021
- U.S. locations
- 631
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 408 more
- Conditions
- Advanced Cancers, Sarcoma
- Interventions
- Hyperthermic Peritoneal Perfusion (HIPEC), Cisplatin
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas